U.S. markets open in 3 hours 3 minutes

Nemaura Medical Inc. (NMRD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.33+0.23 (+3.77%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close6.10
Open6.05
Bid0.00 x 1300
Ask0.00 x 1000
Day's Range6.05 - 6.44
52 Week Range3.12 - 16.50
Volume70,483
Avg. Volume251,186
Market Cap145.149M
Beta (5Y Monthly)-0.12
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateFeb 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Nemaura Medical Launches BEAT®diabetes Smartphone App on Android and iOS Platforms; Begins Pilot Distribution of proBEAT™ Sensors
    GlobeNewswire

    Nemaura Medical Launches BEAT®diabetes Smartphone App on Android and iOS Platforms; Begins Pilot Distribution of proBEAT™ Sensors

    Loughborough, England, April 13, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the launch of its BEAT®diabetes app on the GooglePlay and iOS platforms. The BEATdiabetes app, which is publicly available through the Google Play store and Apple’s app store provides predictive information that supplies the user suggestions such as smart eating choices, exercise and other potential lifestyle changes over the long term based on information provided by the user. It also features continuous one-on-one support through its AI avatar, Lena, who learns about user habits and regularly becomes more familiar with each user. As new information is processed, Lena offers feedback and encouragement as well as helpful ideas to help users not only improve their health, but potentially reverse Type 2 diabetes. The program is based on an in-clinic program originally developed and validated at the Joslin Diabetes Center. The Company is also beginning pilot programs that include its proprietary proBEAT™ monitor, a non-invasive, daily-wear glucose monitoring patch, synced with the BEAT®diabetes program. proBEAT™ is a flexible wear patch, which provides feedback and actionable insights to users to better understand how diet and lifestyle adjustments might impact blood glucose fluctuations, empowering its users with knowledge that can lead to smarter decisions and improved overall health and well-being. “We believe that the BEAT®diabetes app offers a significant new path toward better lifestyle management with the overall aim of providing a better tool for improved management and potential reversal of Type 2 diabetes,” commented Dr. Faz Chowdhury, Nemaura’s Chief Executive Officer. “In addition, we believe our pilot program which includes our proBEAT™ non-invasive glucose sensor ushers in a new era in the development of life management tools that have been scientifically validated and utilize a personalized coaching method that combines a digital platform with data from a unique non-invasive device. We have initially adopted a business-to-business model and are actively exploring a range of options for broad distribution of this combined program through U.S. insurers and employee wellness programs. The sensor technology provides us with a unique position in this market, at a competitive price point. We look forward to discussing further distribution of the proBEAT™ monitor and associated programs as we progress our commercial initiatives.” For additional information access the program website at www.beatdiabetes.life. About Nemaura Medical, Inc. Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program. The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com. Cautionary Statement Regarding Forward-Looking Statements: The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements. Contact: Jules Abraham CORE IR 917-885-7378 julesa@coreir.com

  • Nemaura Medical Retains Paul Kennedy as Advisor for International Growth Opportunities and Member of the Executive Advisory Board
    GlobeNewswire

    Nemaura Medical Retains Paul Kennedy as Advisor for International Growth Opportunities and Member of the Executive Advisory Board

    Loughborough, England, March 25, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it has retained Paul Kennedy who will be advising the Company on its commercial growth initiatives. “Paul brings a wealth of Bio and Medtech experience with many years in the industry in different roles providing a well-rounded background. He spent 15 years at Novo Nordisk, a biotechnology company that focuses on the discovery of more effective treatments for people living with diabetes and other serious chronic diseases, including as CEO of the Company in France. As a result of Paul’s years of experience in the biotech industry, he brings with him a large network that will be invaluable in helping Nemaura in driving its commercial growth initiatives. We look forward to working with Paul and are excited to see the impact he will have in this advisory role,” said Faz Chowdhury, Ph.D., Nemaura’s CEO. About Nemaura Medical, Inc. Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service launched in the USA under the BEATdiabetes.Life program. The Company sits at the intersection of the global Type 2diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com. Cautionary Statement Regarding Forward-Looking Statements: The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements. Contact: Jules Abraham CORE IR 917-885-7378 julesa@coreir.com

  • Nemaura Medical Announces Submission to German Authorities for Reimbursement of its Glucose Monitoring Device
    GlobeNewswire

    Nemaura Medical Announces Submission to German Authorities for Reimbursement of its Glucose Monitoring Device

    Loughborough, England, March 11, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces its submission to G-BA (Gemeinsamer Bundesausschuss) for approval of sugarBEAT®, the Company’s non-invasive, daily wear, continuous glucose monitoring device. The G-BA is the highest decision-making body for joint self-administration in the German health care system, determining medical services that insured people can claim as well as resolving quality assurance measures for practices and hospitals. The G-BA’s primary function is specifying the “service catalog” of the health insurance companies according to the generally recognized state of medical knowledge. Should it be approved for reimbursement, Nemaura would work with Germany’s individual statutory health insurance organizations to determine terms of reimbursement contracts. Dr. Fred Schaebsdau, Nemaura’s Vice President of Strategy and Strategic Alliances is coordinating the effort for the Company. Faz Chowdhury, Ph.D., Nemaura’s CEO commented, “With approximately 73 million insured people in statutory/public sick funds in Germany, the submission to the G-BA for our non-invasive glucose monitoring device provides a significant opportunity for us to increase our penetration in this market and drive future growth of our sugarBEAT® product. There are currently 425 million people around with world with diabetes resulting in a total addressable market of over $150 billion for sugerBEAT. Gaining access to the German market would mark a significant milestone in expanding commercialization and increasing availability and use sugarBEAT®. We look forward to working with the G-BA as we progress through their approval process.” About Nemaura Medical, Inc. Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and is commercially marketed in the US as part of the BEATdiabetes program (BEATdiabetes.Life). The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com. Cautionary Statement Regarding Forward-Looking Statements: The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements. Contact: Jules Abraham CORE IR 917-885-7378 julesa@coreir.com